Loading
A US study collecting blood to develop an artificial intelligence test that reads light scattered by tiny vesicles shed from tumours.
EMERALD (NCT07186296) is an observational study sponsored by EXoPERT with MCRA. It builds a repository to develop artificial intelligence software that analyses surface-enhanced Raman spectroscopy profiles of plasma extracellular vesicles for early detection of five cancers.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,400 participants, a start on 9 May 2025 and primary completion expected on 31 August 2026.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/